Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Program advances to lead compound evaluation in preclinical in vivo models
Preliminary data for in vivo studies are expected in second half of 2023
SAN DIEGO, June 20, 2023 /PRNewswire/ -- Regulus... | June 20, 2023

Related Keywords

San Diego ,California ,United States ,Boston ,Massachusetts ,Lou Gehrig ,Oleg Butovsky ,Howardl Weiner ,Jay Hagan ,Nasdaq ,Regulus Therapeutics Inc ,Exchange Commission ,Foundation For Neurologic Diseases Boston ,Rnas The Company Or Regulus ,Therapeutics Inc ,Amyotrophic Lateral Sclerosis ,Neurologic Diseases ,Chief Executive Officer ,Private Securities Litigation Reform Act ,Regulus Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Program ,Advances ,O ,Head ,Compound ,Evaluation ,N ,Reclinical ,Ivo ,Data ,Or ,Studies ,Fire ,Xpected ,Second ,Calf ,F ,Pune ,023 Rgls Us75915k3095 ,